Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 187

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 187
---
 the working capital requirement in 2024 (versus a net increase of € 413 million in 2023 ), including a decrease in US rebate provisions (€1,330 million) following the decision to reduce the Lantus list price effective January 1, 2024. Net cash provided by/used in continuing investing activities represented a net cash outflow of € 4,298 million in 2024 , compared with a net outflow of € 4,950 million in 2023 . The net outflow in 2024 was mainly a result of the acquisition of Inhibrx.inc ( $2,035 million ). The net outflow in 2023 was mainly a result of the acquisition of Provention Bio, Inc. ( $2,722 million ). Acquisitions of property, plant and equipment and intangible assets amounted to € 3,195 million, versus € 2,906 million in 2023 . There were € 1,733 million of acquisitions of property, plant and equipment (versus € 1,619 million in 2023 ), most of which related to industrial facilities. Acquisitions of intangible assets (€ 1,462 million, versus € 1,287 million in 2023 ) mainly comprised contractual payments for intangible rights under license and collaboration agreements. After-tax proceeds from disposals (€ 1,461 million in 2024 , € 807 million in 2023 ) exclude proceeds from divestments of investments in consolidated undertakings and investments accounted for using the equity method, and mainly comprised the sale of the Enjaymo global rights to Recordati for pre-tax proceeds of €768 million. Net cash provided by/used in continuing financing activities represented a net cash outflow of € 5,751 million in 2024 , compared with a net cash outflow of € 8,048 million in 2023 . The 2024 figure includes the redemption of a €600 million bond issue. Other movements included (i) the dividend payout to our shareholders of € 4,704 million (versus € 4,454 million in 2023 ); and (ii) the effect of changes in our share capital (repurchases of our own shares, net of capital increases), representing a net cash outflow of € 115 million in 2024 versus a net cash outflow of € 398 million in 2023 . The net change in cash and cash equivalents of continuing operations in 2024 was